Document:

Exhibit
4.3

 

THIS
WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”),
OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.5 BELOW, MAY NOT BE OFFERED,
SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY
TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.

 

WARRANT
TO PURCHASE STOCK

 

	Company:	Augmedix,
    Inc., a Delaware corporation
	 	 
	Number
    of Shares:	25,000
	 	 
	Type/Series
    of Stock:	Series
    B Preferred Stock of the Company
	 	 
	Warrant
    Price:	$1.6732
    per share
	 	 
	Issue
    Date:	August
    28, 2018
	 	 
	Expiration
    Date:	August
    28, 2028 (See also Section 1.6)

 

THIS
WARRANT CERTIFIES THAT, for good and valuable consideration, Dignity Health (together with any successor or permitted assignee
or transferee of this Warrant or of any shares issued upon exercise hereof, “Holder”) is entitled to purchase
the number of fully paid and non-assessable shares (the “Shares”) of the above-stated Type/Series of Stock
(the “Class”) of the above-named company (the “Company”) at the above-stated Warrant Price,
all as set forth above and as adjusted pursuant to SECTION 2 of this Warrant, subject to the provisions and upon the terms
and conditions set forth in this Warrant.

 

SECTION
1 EXERCISE.

 

1.1
Method of Exercise/Exchange. Holder may at any time and from time to time exercise this Warrant, in whole or in part, by
delivering to the Company the original of this Warrant together with a duly executed Notice of Exercise/Exchange in substantially
the form attached hereto as Appendix 1 and, unless Holder is exchanging this Warrant pursuant to a cashless exchange set forth
in Section 1.2 a check, wire transfer of same-day funds (to an account designated by the Company), or other form of payment
acceptable to the Company for the aggregate Warrant Price for the Shares being purchased.

 

1.2
Cashless Exchange. In lieu of payment of the aggregate Warrant Price in the manner as specified in Section 1.1 above,
but otherwise in accordance with the requirements of Section 1.1, Holder shall have the right to exchange this Warrant
or any portion hereof for a number of Shares equal to the value of this Warrant, or portion hereof as to which this Warrant is
being exchanged. Thereupon, the Company shall issue to the Holder such number of fully paid and non-assessable Shares as are computed
using the following formula:

 

X
= Y(A-B)/A

 

    1

     

    

 

where:

 

X
= the number of Shares to be issued to the Holder;

 

Y
= the number of Shares with respect to which this Warrant is being exchanged (inclusive of the Shares surrendered to the Company
in satisfaction of the aggregate Warrant Price);

 

A
= the Fair Market Value (as determined pursuant to Section 1.3 below) of one Share; and

 

B
= the Warrant Price.

 

1.3
Fair Market Value. If the Company’s common stock is then traded or quoted on a nationally recognized securities exchange,
inter-dealer quotation system or over-the-counter market (a “Trading Market”) and the Class is common stock,
the fair market value of a Share shall be the closing price or last sale price of a share of common stock reported for the Business
Day immediately before the date on which Holder delivers this Warrant together with its Notice of Exercise/Exchange to the Company.
If the Company’s common stock is then traded in a Trading Market and the Class is a series of the Company’s convertible
preferred stock, the fair market value of a Share shall be the closing price or last sale price of a share of the Company’s
common stock reported for the Business Day immediately before the date on which Holder delivers this Warrant together with its
Notice of Exercise/Exchange to the Company multiplied by the number of shares of the Company’s common stock into which a
Share is then convertible. If the Company’s common stock is not traded in a Trading Market, the Board of Directors of the
Company shall determine the fair market value of a Share in its reasonable good faith judgment.

 

1.4
Delivery of Certificate and New Warrant. Promptly after Holder exercises or exchanges this Warrant in the manner set forth
in Section 1.1 or 1.2 above, the Company shall deliver to Holder a certificate representing the Shares issued to
Holder upon such exercise and, if this Warrant has not been fully exercised or exchanges and has not expired, a new warrant of
like tenor representing the Shares not so acquired.

 

1.5 Replacement
of Warrant. On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation
of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory
in form, substance and amount to the Company or, in the case of mutilation, on surrender of this Warrant to the Company for
cancellation, the Company shall, within a reasonable time, execute and deliver to Holder, in lieu of this Warrant, a new
warrant of like tenor and amount.

 

1.6
Treatment of Warrant Upon Acquisition of Company.

 

(a)
Acquisition. For the purpose of this Warrant, “Acquisition” means any transaction or series of related
transactions involving: (i) the sale, lease, exclusive license or other disposition of all or substantially all of the assets
of the Company; (ii) any merger or consolidation of the Company into or with another person or entity (other than a merger or
consolidation effected exclusively to change the Company’s domicile), or any other corporate reorganization, in which the
stockholders of the Company in their capacity as such immediately prior to such merger, consolidation or reorganization, own less
than a majority of the Company’s (or the surviving or successor entity’s) outstanding voting power immediately after
such merger, consolidation or reorganization; (iii) any sale or other transfer by the stockholders of the Company of shares representing
at least a majority of the Company’s then-total outstanding combined voting power.

 

    2

     

    

 

 

(b)
Treatment of Warrant in Cash/Public Acquisition. In the event of an Acquisition in which the consideration to be received
by the Company’s stockholders consists solely of cash, solely of Marketable Securities or a combination of cash and Marketable
Securities (a “Cash/Public Acquisition”), and the fair market value of one Share as determined in accordance
with Section 1.3 above would be greater than the Warrant Price in effect on such date immediately prior to such Cash/Public
Acquisition, and Holder has not exercised this Warrant pursuant to Section 1.1 above as to all Shares, then this Warrant
shall automatically be deemed to be exchanged pursuant to Section 1.2 above as to all Shares effective immediately prior
to and contingent upon the consummation of a Cash/Public Acquisition. In connection with such exchange, Holder shall be deemed
to have restated each of the representations and warranties in Section 4 of the Warrant as the date thereof and the Company
shall promptly notify the Holder of the number of Shares (or such other securities) issued upon exercise or exchange. In the event
of a Cash/Public Acquisition where the fair market value of one Share as determined in accordance with Section 1.3 above
would be less than the Warrant Price in effect immediately prior to such Cash/Public Acquisition, then this Warrant will expire
immediately prior to the consummation of such Cash/Public Acquisition.

 

(c)
Sale Right in a Cash Acquisition. Notwithstanding the foregoing, in connection with an Acquisition in which the consideration
to be received by the Company’s stockholders is primarily cash, Holder shall have the right in lieu of the foregoing to
exchange this Warrant or any portion hereof for a lump-sum cash payment equal to the value of this Warrant, or portion hereof
as to which this Warrant is being exchanged. Any payments made by the Company to the Holder pursuant to this Warrant shall be
made without any deduction or withholding for or on account of taxes or otherwise. Thereupon, the Company shall pay to the Holder
such lump-sum cash payment equal to the product of “X” multiplied by “A,” each as determined in accordance
with Section 1.2 above.

 

(d)
Treatment of Warrant in Other Acquisitions. Upon the closing of any Acquisition other than a Cash/Public Acquisition defined
above, the acquiring, surviving or successor entity shall assume the obligations of this Warrant, and this Warrant shall thereafter
be exercisable for the same securities and/or other property as would have been paid for the Shares issuable upon exercise of
the unexercised portion of this Warrant as if such Shares were outstanding on and as of the closing of such Acquisition, subject
to further adjustment from time to time in accordance with the provisions of this Warrant; provided, however, that if the fair
market value of one Share as determined in accordance with Section 1.3 above in such Acquisition is greater than three
times the Warrant Price then in effect then the acquiring, surviving or successor entity may elect not to assume the obligations
of this Warrant and this Warrant shall terminate upon the consummation of such Acquisition, provided further, however, that the
acquiring, surviving or successor entity and the Company shall give the Holder notice in accordance with Section 3.3(d)
of this Warrant and reasonable opportunity to exercise or exchange this Warrant prior to the consummation of such Acquisition,
and in any event the provisions of Section 5.1(b) shall be applicable upon such expiration.

 

(e)
As used in this Warrant, “Marketable Securities” means securities meeting all of the following requirements:
(i) the issuer thereof is then subject to the reporting requirements of Section 13 or Section 15(d) of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), and is then current in its filing of all required reports and
other information under the Securities Act of 1933, as amended (the “Act”) and the Exchange Act; (ii) the class and
series of shares or other security of the issuer that would be received by Holder in connection with the Acquisition were Holder
to exercise this Warrant on or prior to the closing thereof is then traded in Trading Market; and (iii) Holder would be able to
publicly re-sell, within six months following the closing of such Acquisition, all of the issuer’s shares and/or other securities
that would be received by Holder in such Acquisition were Holder to exercise this Warrant in full on or prior to the closing of
such Acquisition.

 

    3

     

    

 

SECTION
2 ADJUSTMENTS TO THE SHARES AND WARRANT PRICE.

 

2.1
Stock Dividends, Splits, Etc. If the Company declares or pays a dividend or distribution on the outstanding shares of the
Class payable in common stock or other securities or property (other than cash), then upon exercise of this Warrant, for each
Share acquired, Holder shall receive, without additional cost to Holder, the total number and kind of securities and property
which Holder would have received had Holder owned the Shares of record as of the date the dividend or distribution occurred. If
the Company subdivides the outstanding shares of the Class by reclassification or otherwise into a greater number of shares, the
number of Shares purchasable hereunder shall be proportionately increased and the Warrant Price shall be proportionately decreased,
provided the aggregate purchase price shall remain the same. If the outstanding shares of the Class are combined or consolidated,
by reclassification or otherwise, into a lesser number of shares, the Warrant Price shall be proportionately increased and the
number of Shares shall be proportionately decreased, provided the aggregate purchase price shall remain the same.

 

2.2
Reclassification, Exchange, Combinations or Substitution. Upon any event whereby all of the outstanding shares of the Class
are reclassified, exchanged, combined, substituted, or replaced for, into, with or by Company securities of a different class
and/or series, then from and after the consummation of such event, this Warrant will be exercisable for the number, class and
series of Company securities that Holder would have received had the Shares been outstanding on and as of the consummation of
such event, provided the aggregate purchase price shall remain the same and subject to further adjustment thereafter from time
to time in accordance with the provisions of this Warrant. The provisions of this Section 2.2 shall similarly apply to
successive reclassifications, exchanges, combinations, substitutions, replacements or other similar events.

 

2.3
Conversion of Preferred Stock. If the Class is a class and series of the Company’s convertible preferred stock, in
the event that all outstanding shares of the Class are converted, automatically or by action of the holders thereof, into common
stock pursuant to the provisions of the Company’s Certificate of Incorporation (the “Charter”), including,
without limitation, in connection with the Company’s initial, underwritten public offering and sale of its common stock
pursuant to an effective registration statement under the Act (the “IPO”), then from and after the date on which all
outstanding shares of the Class have been so converted, this Warrant shall be exercisable for such number of shares of common
stock into which the Shares would have been converted had the Shares been outstanding on the date of such conversion, and the
Warrant Price shall equal the Warrant Price in effect as of immediately prior to such conversion divided by the number of shares
of common stock into which one Share would have been converted, all subject to further adjustment thereafter from time to time
in accordance with the provisions of this Warrant.

 

2.4
Adjustments for Diluting Issuances. The Type/Series of Stock issuable upon exercise of this Warrant shall have the same
original issue price and conversion price as all other shares of the same Type/Series Stock of the Company. For the avoidance
of doubt, this means that if there is an adjustment to the conversion price of the Type/Series of Stock prior to the exercise
of this Warrant then the shares of the Type/Series of Stock (or Common Stock issuable upon conversion of such shares) shall have
the same conversion price as other outstanding shares of the same Type/Series notwithstanding that an adjustment to the conversion
price occurred prior to the exercise of this Warrant.

 

    4

     

    

 

2.5
No Fractional Share. No fractional Share shall be issuable upon exercise of this Warrant and the number of Shares to be
issued shall be rounded down to the nearest whole Share. If a fractional Share interest arises upon any exercise of the Warrant,
the Company shall eliminate such fractional Share interest by paying Holder in cash the amount computed by multiplying the fractional
interest by (a) the fair market value (as determined in accordance with Section 1.3 above) of a full Share, less (b) the
then-effective Warrant Price.

 

2.6
Notice/Certificate as to Adjustments. Upon each adjustment of the Warrant Price, Class and/or number of Shares, the Company,
at the Company’s expense, shall notify Holder in writing within a reasonable time setting forth the adjustments to the Warrant
Price, Class and/or number of Shares and facts upon which such adjustment is based. The Company shall, upon written request from
Holder, furnish Holder with a certificate of its Chief Executive Officer or Chief Financial Officer, including computations of
such adjustment and the Warrant Price, Class and number of Shares in effect upon the date of such adjustment.

 

SECTION
3 REPRESENTATIONS AND COVENANTS OF THE COMPANY.

 

3.1
Representations and Warranties. The Company represents and warrants to, and agrees with, the Holder as follows:

 

(a)
The initial Warrant Price referenced on the first page of this Warrant is not greater than the price per share at which shares
of the Class were last sold and issued prior to the Issue Date hereof in an arms-length transaction in which at least $41,830
of such shares were sold.

 

(b)
This Warrant is, and all Shares which may be issued upon the exercise of this Warrant, all securities, if any, issuable upon conversion
of the Shares and any warrants issued in substitution for or replacement of this Warrant shall, upon issuance, be duly authorized,
validly issued, fully paid and non-assessable, and free of any taxes, liens, charges and encumbrances except for restrictions
on transfer provided for herein or under applicable federal and state securities laws. The Company covenants that it shall at
all times cause to be reserved and kept available out of its authorized and unissued capital stock such number of shares of the
Class, common stock and other securities as will be sufficient to permit the exercise in full of this Warrant and the conversion
of the Shares into common stock or such other securities.

 

(c)
The Company’s capitalization table attached hereto as Schedule 1 is true and complete, in all material respects, as of the
Issue Date.

 

(d)
The Company (i) has been duly incorporated and is validly existing as a corporation in good standing under the laws of Delaware,
with full corporate power and authority to own or lease, as the case may be, and to operate its properties and conduct its business
as presently conducted, and (ii) is duly qualified to do business as a foreign corporation and is in good standing under the laws
of each jurisdiction which requires such qualification, except in the case of clause (ii) above, to the extent that the failure
to be so qualified or be in good standing would not reasonably be expected to result in (i) a material adverse effect on the validity
or enforceability of this Warrant, (ii) a material adverse effect on the condition (financial or otherwise), earnings, business
or properties of the Company, or (iii) a material adverse effect on the Company’s ability to perform in any material respect
its obligations under this Warrant (any of (i), (ii) or (iii)) (a “Material Adverse Effect”).

 

    5

     

    

 

(e)
The Company has all requisite corporate power and authority, and has taken all requisite corporate action, to execute and deliver
this Warrant, sell and issue the Shares and carry out and perform all of its obligations under this Warrant, and without
limiting the foregoing, the Company hereby agrees that the Company shall all times have authorized and reserved the number of
Shares needed to provide for the exercise of the rights then represented by this Warrant. If at any time the Company does not
have a sufficient number of Shares authorized and available, then the Company shall call and hold a special meeting of its stockholders
within 60 days of that time for the sole purpose of increasing the number of authorized Shares to a sufficient number. This Warrant
constitutes the legal, valid and binding obligation of the Company, enforceable in accordance with its terms, except (i) as limited
by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or affecting the enforcement of creditors’
rights generally and (ii) as limited by equitable principles generally, including any specific performance.

 

(f)
No consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any
federal, state, or local governmental authority on the part of the Company is required in connection with the consummation of
the transactions contemplated by this Warrant except for the filing of a Form D with the Securities and Exchange Commission (the
“Commission”) under the Securities Act and compliance with the securities and blue sky laws in the states and
other jurisdictions in which shares of Common Stock are offered and/or sold, which compliance will be effected in accordance with
such laws.

 

(g)
Neither the execution, delivery or performance of this Warrant by the Company nor the consummation of any of the transactions
contemplated thereby (including, without limitation, the issuance and sale by the Company of the Shares) will conflict with, result
in a breach or violation of, or imposition of any lien, charge or encumbrance upon any property or assets of the Company pursuant
to, (i) the charter or by-laws of the Company, (ii) the terms of any indenture, contract, lease, mortgage, deed of trust, note
agreement, loan agreement or other agreement, obligation, condition, covenant or instrument to which the Company is a party or
bound or to which its or their property is subject, or (iii) any statute, law, rule, regulation, judgment, order or decree applicable
to the Company of any court, regulatory body, administrative agency, governmental body, arbitrator or other authority having jurisdiction
over the Company or any of its properties, except in the case of clauses (ii) and (iii) above, for any conflict, breach or violation
of, or imposition that would not, individually or in the aggregate, have a Material Adverse Effect.

 

(h)
Neither the Company nor any Person acting on its behalf, has engaged in any form of general solicitation or general advertising
(within the meaning of Regulation D promulgated under the Securities Act) in connection with the offer or sale of this Warrant.

 

(i)
Neither of the Company or any Person acting on its behalf has, directly or indirectly, made any offers or sales of any security
or solicited any offers to buy any Company security, under circumstances that would adversely affect reliance by the Company on
Section 4(a)(2) of the Securities Act or require registration of this Warrant under the Securities Act or cause this Warrant to
be integrated with prior offerings by the Company for purposes of the Securities Act.

 

3.2
Registration Rights/Investor Rights Agreement. The Company shall take such actions as are necessary to provide that the
Holder, upon exercise of this Warrant, is a party to the Company’s Investor Rights Agreement and entitled to “piggyback”
and S-3 registration rights.

 

    6

     

    

 

3.3
Notice of Certain Events. If the Company proposes at any time to:

 

(a)
declare any dividend or distribution upon the outstanding shares of the Class or common stock, whether in cash, property, stock,
or other securities and whether or not a regular cash dividend;

 

(b)
offer for subscription or sale pro rata to the holders of the outstanding shares of the Class any additional shares of any class
or series of the Company’s stock (other than pursuant to contractual pre-emptive rights);

 

(c)
effect any reclassification, exchange, combination, substitution, reorganization or recapitalization of the outstanding shares
of the Class;

 

(d)
effect an Acquisition or to liquidate, dissolve or wind up; or

 

(e)
effect an IPO;

 

then,
in connection with each such event, the Company shall give Holder:

 

(1)
at least seven Business Days prior written notice of the date on which a record will be taken for such dividend, distribution,
or subscription rights (and specifying the date on which the holders of outstanding shares of the Class will be entitled thereto)
or for determining rights to vote, if any, in respect of the matters referred to in (a) and (b) above;

 

(2)
in the case of the matters referred to in (c) and (d) above at least seven Business Days prior written notice of the date when
the same will take place (and specifying the date on which the holders of outstanding shares of the Class will be entitled to
exchange their shares for the securities or other property deliverable upon the occurrence of such event); and

 

(3)
with respect to the IPO, at least seven Business Days prior written notice of the date on which the Company proposes to file its
registration statement in connection therewith.

 

Company
will also provide information requested by Holder that is reasonably necessary to enable Holder to comply with Holder’s
accounting or reporting requirements.

 

SECTION
4 REPRESENTATIONS AND WARRANTIES OF THE HOLDER. 

 

The
Holder represents and warrants to the Company as follows:

 

4.1
Purchase for Own Account. This Warrant and the securities to be acquired upon exercise of this Warrant by Holder are being
acquired for investment for Holder’s account, not as a nominee or agent, and not with a view to the public resale or distribution
within the meaning of the Act. Holder also represents that it has not been formed for the specific purpose of acquiring this Warrant
or the Shares.

 

4.2
Disclosure of Information. Holder is aware of the Company’s business affairs and financial condition and has received
or has had full access to all the information it considers necessary or appropriate to make an informed investment decision with
respect to the acquisition of this Warrant and its underlying securities. Holder further has had an opportunity to ask questions
and receive answers from the Company regarding the terms and conditions of the offering of this Warrant and its underlying securities
and to obtain additional information (to the extent the Company possessed such information or could acquire it without unreasonable
effort or expense) necessary to verify any information furnished to Holder or to which Holder has access.

 

    7

     

    

 

4.3
Investment Experience. Holder understands that the purchase of this Warrant and its underlying securities involves substantial
risk. Holder has experience as an investor in securities of companies in the development stage and acknowledges that Holder can
bear the economic risk of such Holder’s investment in this Warrant and its underlying securities and has such knowledge
and experience in financial or business matters that Holder is capable of evaluating the merits and risks of its investment in
this Warrant and its underlying securities and/or has a preexisting personal or business relationship with the Company and certain
of its officers, directors or controlling persons of a nature and duration that enables Holder to be aware of the character, business
acumen and financial circumstances of such persons.

 

4.4
Accredited Investor Status. Holder is an “accredited investor” within the meaning of Regulation D promulgated
under the Act.

 

4.5
The Act. Holder understands that this Warrant and the Shares issuable upon exercise hereof have not been registered under
the Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature
of the Holder’s investment intent as expressed herein. Holder understands that this Warrant and the Shares issued upon any
exercise hereof must be held indefinitely unless subsequently registered under the Act and qualified under applicable state securities
laws, or unless exemption from such registration and qualification are otherwise available. Holder is aware of the provisions
of Rule 144 promulgated under the Act.

 

4.6
Market Stand-off Agreement. Holder agrees that the Shares shall be subject to the Market Standoff provisions set forth
in Section 3.11 of that certain Amended and Restated Investors’ Rights Agreement dated May 2, 2018 by and among the Company
and certain investors of the Company listed on Schedule A thereto and certain stockholders of the Company listed on Schedule
B thereto, as may be amended, provided that Holder shall not be bound by any amendment that affects Holder’s rights
under the Loan Agreement or affects it in a manner that is different from other holders under such agreement.

 

4.7
No Voting Rights. Holder, as a Holder of this Warrant, will not have any voting rights until the exercise of this Warrant
and, except as expressly set forth in this Warrant, will not be considered a stockholder for any purpose until the exercise of
this Warrant.

 

SECTION
5 MISCELLANEOUS.

 

5.1
(a) Term and Automatic Conversion Upon Expiration. Subject to the provisions of Section 1.6 above, this Warrant
is exercisable in whole or in part at any time and from time to time on or before 6:00 P.M. Pacific time, on the Expiration Date
and shall be void thereafter.

 

(b)
Automatic Cashless Exchange upon Expiration. In the event that, upon the Expiration Date, the fair market value of one
Share (or other security issuable upon the exercise hereof) as determined in accordance with Section 1.3 above is greater
than the Warrant Price in effect on such date, then this Warrant shall automatically be deemed on and as of such date to be exchanged
pursuant to Section 1.2 above as to all Shares (or such other securities) for which it shall not previously have been exercised,
and the Company shall, within a reasonable time, deliver a certificate representing the Shares (or such other securities) issued
upon such exchange to Holder.

 

    8

     

    

 

5.2
Legends. The Shares (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) shall
be imprinted with a legend in substantially the following form:

 

THE
SHARES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”),
OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN THAT CERTAIN WARRANT TO PURCHASE STOCK ISSUED BY THE ISSUER TO
DIGNITY HEALTH DATED AUGUST 28, 2018, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER
SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM
SUCH REGISTRATION.

 

THE
SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE, INCLUDING A LOCK-UP PERIOD IN
THE EVENT OF A PUBLIC OFFERING, AS SET FORTH IN AN INVESTORS’ RIGHTS AGREEMENT, A COPY OF WHICH MAY BE OBTAINED AT THE PRINCIPAL
OFFICE OF ISSUER.

 

5.3
Compliance with Securities Laws on Transfer. This Warrant and the Shares issuable upon exercise of this Warrant (and the
securities issuable, directly or indirectly, upon conversion of the Shares, if any) may not be transferred or assigned in whole
or in part except in compliance with applicable federal and state securities laws by the transferor and the transferee (including,
without limitation, the delivery of investment representation letters and legal opinions reasonably satisfactory to the Company,
as reasonably requested by the Company). The Company shall not require Holder to provide an opinion of counsel if the transfer
is to any affiliate of Holder, provided that any such transferee is an “accredited investor” as defined in
Regulation D promulgated under the Act. Additionally, the Company shall also not require an opinion of counsel if there is no
material question as to the availability of Rule 144 promulgated under the Act.

 

5.4
No Impairment; Further Assurances. The Company will not, by amendment of its Charter or through any reorganization, transfer
of assets, consolidation, merger, dissolution, issue or sale of securities, or any other voluntary action, avoid or seek to avoid
the observance or performance of any of the terms to be observed or performed by it hereunder, but will at all times in good faith
assist in the carrying out of all the provisions of this Warrant and in the taking of all such action as may reasonably be requested
by Holder in order to protect the exercise privilege of Holder against dilution or other impairment, consistent with the tenor
and purpose of this Warrant. If the provisions of the Company’s Certificate of Incorporation defining the economic rights
granted to holders of the Class of Preferred Stock are restated, amended, modified, waived or otherwise affected in any manner
adverse to the Holder, without the Holder’s prior written consent, then the Holder may elect, in its sole and absolute discretion,
not to be bound by such adverse action, and the amended, modified, or waived provision of the Company’s Certificate of Incorporation
shall not apply to Holder, with regard to the Preferred Stock, or any other rights granted pursuant to this Warrant (the “Holder
Election”). The Holder Election shall only apply to Holder’s economic rights and shall not apply to any voting
or governance rights that may be held by Holder. For the avoidance of doubt, the Holder Election shall also not confer upon Holder
any additional voting and/or governance rights regardless of any modifications to the Company’s Certificate of Incorporation
that are necessary to satisfy the requirements of this Section 5.4. The Company will not increase the par value
of any Shares above the Warrant Price then in effect, and (ii) will take all such actions as may be necessary or appropriate in
order that the Company may validly and legally issue fully paid and non-assessable Shares upon the exercise of this Warrant.

 

    9

     

    

 

5.5
Transfer Procedure. Subject to the provisions of Section 5.3 and upon providing the Company with written notice,
Holder may transfer all or part of this Warrant or the Shares issuable upon exercise of this Warrant (or the securities issuable
directly or indirectly, upon conversion of the Shares, if any) to any transferee, provided, however, in connection with
any such transfer, Holder will give the Company notice of the portion of the Warrant being transferred with the name, address
and taxpayer identification number of the transferee and vHolder will surrender this Warrant to the Company for reissuance to the
transferee(s) (and Holder if applicable); and provided further, that any subsequent transferee shall agree in writing with
the Company to be bound by all of the terms and conditions of this Warrant (including the representations, warranties and covenants
set forth in Section 4 hereof).

 

5.6
Binding on Successors. This Warrant will be binding upon any entity succeeding to the Company by merger, consolidation
or acquisition of all or substantially all of the Company’s assets.

 

5.7
Taxes. The Company will pay all taxes (other than taxes based upon income) and other governmental charges that may be imposed
with respect to the issuance or delivery of the Shares, other than any tax or other charge imposed in connection with any transfer
involved in the issue and delivery of the Shares in a name other than that of the Holder.

 

5.8
Notices. All notices and other communications hereunder from the Company to the Holder, or vice versa, shall be deemed
delivered and effective (i) when given personally, (ii) on the third Business Day after being mailed by first-class registered
or certified mail, postage prepaid, (iii) upon actual receipt if given by facsimile or electronic mail and such receipt is confirmed
in writing by the recipient, or (iv) on the first Business Day following delivery to a reliable overnight courier service, courier
fee prepaid, in any case at such address as may have been furnished to the Company or Holder, as the case may be, in writing by
the Company or such Holder from time to time in accordance with the provisions of this Section 5.5 All notices to Holder
shall be addressed as follows until the Company receives notice of a change of address in connection with a transfer or otherwise:

 

Dignity
Health

Attn:
[*]

185 Berry Street, Suite 300

San
Francisco, California 94107

	 	Telephone:	[*]

 

Email
address: [*]

With
a copy (which shall not constitute notice) to:

 

Dignity
Health

Attention:
[*]

185
Berry Street, Suite 300

San
Francisco, California 94107

 

Email: [*]

 

    10

     

    

 

Notice
to the Company shall be addressed as follows until Holder receives notice of a change in address:

 

Augmedix,
Inc.

1161
Mission Street, Suite 210

San
Francisco, CA 94103

Attention:
Matteo Marchetta, Chief Financial Officer

 

With
a copy (which shall not constitute notice) to:

 

Fenwick
& West LLP

801
California St.

Mountain
View, CA 94041

Attention:
[*]

Email: [*]

 

5.9
Waiver. This Warrant and any term hereof may be changed, waived, discharged or terminated (either generally or in a particular
instance and either retroactively or prospectively) only by an instrument in writing signed by the party against which enforcement
of such change, waiver, discharge or termination is sought.

 

5.10
Attorneys’ Fees. In the event of any dispute between the parties concerning the terms and provisions of this Warrant,
the party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such dispute, including
reasonable attorneys’ fees.

 

5.11
Counterparts; Facsimile/Electronic Signatures. This Warrant may be executed in counterparts, all of which together shall
constitute one and the same agreement. Any signature page delivered electronically or by facsimile shall be binding to the same
extent as an original signature page with regards to any agreement subject to the terms hereof or any amendment thereto.

 

5.12
Governing Law. This Warrant shall be governed by and construed in accordance with the laws of the State of Delaware, without
regard to conflict of law principles that would result in the application of any other than the laws of the State of Delaware.

 

5.13
Waiver of Jury Trial. AS A MATERIAL INDUCEMENT FOR EACH PARTY HERETO TO ENTER INTO THIS WARRANT, THE PARTIES HERETO HEREBY
WAIVE ANY RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING RELATED IN ANY WAY TO THIS WARRANT AND/OR ANY AND ALL OF THE OTHER DOCUMENTS
ASSOCIATED WITH THIS TRANSACTION.

 

5.14
Headings. The headings in this Warrant are for purposes of reference only and shall not limit or otherwise affect the meaning
of any provision of this Warrant.

 

5.15
Business Days. “Business Day” is any day that is not a Saturday, Sunday or a day on which banks in New York
or Arizona are closed.

 

[Signature
page follows]

 

    11

     

    

 

IN
WITNESS WHEREOF, the parties have caused this Warrant to Purchase Stock to be executed by their duly authorized representatives
effective as of the Issue Date written above.

 

	“COMPANY”	 
	 	 	 
	AUGMEDIX, INC., a Delaware corporation	 
	 	 	 
	By:	/s/
    Manny Krakaris	 
	Name:  
    	Manny
    Krakaris	 
	Title:
    	Chief
    Executive Officer	 
	 	 	 
	“HOLDER”	 
	 	 	 
	DIGNITY HEALTH, a California nonprofit public benefit corporation	 
	 	 	 
	By:	/s/
    Lisa Zuckerman	 
	 	Lisa
    Zuckerman	 
	 	Its:
    Senior Vice President	 

 

     

     

    

 

APPENDIX
1

 

NOTICE
OF EXERCISE/EXCHANGE

 

1.
The undersigned Holder hereby exercises its right purchase/exchange [circle one]               
shares of the Common/Series           Preferred [circle one] Stock of
Augmedix, Inc., a Delaware corporation (the “Company”) in accordance with the attached Warrant To Purchase
Stock, and tenders payment of the aggregate Warrant Price for such shares as follows:

 

	 	☐	check
    in the amount of $ payable to order of the Company enclosed herewith
	 	 	 
	 	☐	Wire
    transfer of immediately available funds to the Company’s account
	 	 	 
	 	☐	Cashless
    Exchange pursuant to Section 1.2 of the Warrant
	 	 	 
	 	☐	Other
    [Describe] _______________________________________

 

2.
Please issue a certificate or certificates representing the Shares in the name specified below:

 

	 	 	 	 
	 	 	Holder’s
    Name	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	(Address)	 

 

3.
By its execution below and for the benefit of the Company, Holder hereby restates each of the representations and warranties in
SECTION 4 of the Warrant to Purchase Stock as of the date hereof.

 

	 	HOLDER:	 
	 	 	 
	 	By:	 
	 	 	 
	 	Name:	 
	 	 	 
	 	Title:
    	 
	 	 	 
	 	(Date):	 

 

     

     

    

 

SCHEDULE
1

 

Company
Capitalization TableExhibit 4.4

 

THIS
WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”),
OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED
EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS IN ACCORDANCE WITH APPLICABLE REGISTRATION REQUIREMENTS
OR AN EXEMPTION THEREFROM. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE ISSUER
THAT SUCH OFFER, SALE, TRANSFER, PLEDGE OR HYPOTHECATION OTHERWISE COMPLIES WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS.
This warrant must be surrendered to the coMPANY or its transfer agent as a condition precedent
to the sale, transfer, pledge or hypothecation of any interest in any of the securities represented hereby.

 

WARRANT TO PURCHASE SHARES OF SERIES
B PREFERRED STOCK

of

AUGMEDIX, INC.

 

Dated as of September 3, 2019

Void
after the date specified in Section 8

 

THIS
CERTIFIES THAT, for value received, [________________] or its registered assigns (the “Holder”), is entitled,
subject to the provisions and upon the terms and conditions set forth herein, to purchase from Augmedix, Inc., a Delaware corporation
(the “Company”), shares of the Shares (as defined below), in the amounts, at such times and at the price
per share set forth in Section 1. The term “Warrant” as used
herein shall include this Warrant and any warrants delivered in substitution or exchange therefor as provided herein. This Warrant
is issued in connection with and pursuant to the terms of the 2019 Series B Preferred Stock and Warrant Purchase Agreement dated
September 3, 2019 (the “Agreement”) by and among the Company, the original Holder hereof, and certain
of the Investors (as defined therein) by and among the Company and the Warrant Holders (as defined therein). This Warrant is one
of a series of warrants which may be issued pursuant to the Agreement (collectively, the “Warrants”).

 

The following is a
statement of the rights of the Holder and the conditions to which this Warrant is subject, and to which Holder, by acceptance of
this Warrant, agrees:

 

1. Number
and Price of Shares; Exercise Period.

 

(a) Definition
of Shares. “Shares” shall mean the Series B Preferred Stock of the Company.

 

(b) Number
of Shares. Subject to any previous exercise of the Warrant, the Holder shall have the right to purchase up to _______________
Shares.

 

(c) Exercise
Price. The exercise price per Share (the “Exercise Price”) shall be equal to $1.2111 subject
to adjustment as set forth herein.

 

(d) Exercise
Period. This Warrant shall be exercisable, in whole or in part, at any time after the issuance hereof and prior to the
expiration of this Warrant as set forth in Section 8.

 

    - 1 -

     

    

 

2. Exercise
of the Warrant.

 

(a) Exercise.
The purchase rights represented by this Warrant may be exercised at the election of the Holder, in whole or in part, in accordance
with Section 1, by:

 

(i) the
tender to the Company at its principal office (or such other office or agency as the Company may designate) of a notice of exercise
in the form of Exhibit A (the “Notice of Exercise”), duly completed and executed by or on behalf
of the Holder, together with the surrender of this Warrant; and

 

(ii) the
payment to the Company of an amount equal to (x) the Exercise Price multiplied by (y) the number of Shares being purchased,
by wire transfer or certified, cashier’s or other check acceptable to the Company and payable to the order of the Company.

 

(b) Net
Issue Exercise. In lieu of exercising this Warrant pursuant to Section 2(a)(ii),
if the fair market value of one Share is greater than the Exercise Price (at the date of calculation as set forth below), the Holder
may elect to receive a number of Shares equal to the value of this Warrant (or of any portion of this Warrant being canceled) by
surrender of this Warrant at the principal office of the Company (or such other office or agency as the Company may designate)
together with a properly completed and executed Notice of Exercise reflecting such election, in which event the Company shall issue
to the Holder that number of Shares computed using the following formula:

 

	X	=	Y (A – B)
	A

 

Where:

 

	X	=	The number of Shares to be issued to the Holder
	Y	=	The number of Shares purchasable under this Warrant or, if only a portion of the Warrant is being exercised, the portion of the Warrant being canceled (at the date of such calculation)
	A	=	The fair market value of one Share (at the date of such calculation)
	B	=	The Exercise Price (as adjusted to the date of such calculation)

 

For purposes of the
calculation above, the fair market value of one Share shall be determined by the Board of Directors of the Company, acting in good
faith; provided, however, that:

 

(i) where
a public market exists for the Company’s common stock at the time of such exercise, the fair market value per Share shall
be the average of the closing bid prices of the common stock or the closing price quoted on the national securities exchange on
which the common stock is listed as published in the Wall Street Journal, as applicable, for the ten (10) trading day period
ending five (5) trading days prior to the date of determination of fair market value; and

 

(ii) if
the Warrant is exercised in connection with the Company’s initial public offering of common stock, the fair market value
per Share shall be the product of (x) the per share offering price to the public of the Company’s initial public offering
and (y) the number of shares of common stock into which each Share is convertible at the time of such exercise, as applicable.

 

    - 2 -

     

    

 

(c) Stock
Certificates. The rights under this Warrant shall be deemed to have been exercised and the Shares issuable upon such exercise
shall be deemed to have been issued immediately prior to the close of business on the date this Warrant is exercised in accordance
with its terms, and the person entitled to receive the Shares issuable upon such exercise shall be treated for all purposes as
the holder of record of such Shares as of the close of business on such date. As promptly as reasonably practicable on or after
such date, the Company shall issue and deliver to the person or persons entitled to receive the same a certificate or certificates
for that number of shares issuable upon such exercise. In the event that the rights under this Warrant are exercised in part and
have not expired, the Company shall execute and deliver a new Warrant reflecting the number of Shares that remain subject to this
Warrant.

 

(d) No
Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of the rights under this Warrant. In lieu of such fractional share to which the Holder would otherwise be entitled, the Company
shall make a cash payment equal to the Exercise Price multiplied by such fraction.

 

(e) Automatic
Exercise. If the Holder of this Warrant has not elected to exercise this Warrant prior to expiration of this Warrant pursuant
to Section 8, then this Warrant shall automatically (without any act on the part of the Holder) be exercised pursuant to Section 2(b)
effective immediately prior to the expiration of the Warrant to the extent such net issue exercise would result in the issuance
of Shares, unless Holder shall earlier provide written notice to the Company that the Holder desires that this Warrant expire unexercised.
If this Warrant is automatically exercised, the Company shall notify the Holder of the automatic exercise as soon as reasonably
practicable, and the Holder shall surrender the Warrant to the Company in accordance with the terms hereof.

 

(f) Intentionally
Omitted.

 

(g) Reservation
of Stock. The Company agrees during the term the rights under this Warrant are exercisable to take all reasonable action
to reserve and keep available from its authorized and unissued shares of preferred stock for the purpose of effecting the exercise
of this Warrant such number of shares (and shares of common stock for issuance on conversion of such shares) as shall from time
to time be sufficient to effect the exercise of the rights under this Warrant; and if at any time the number of authorized but
unissued shares of preferred stock and shares of common stock for issuance on conversion of such shares shall not be sufficient
for purposes of the exercise of this Warrant in accordance with its terms and the conversion of the Shares, without limitation
of such other remedies as may be available to the Holder, the Company will use all reasonable efforts to take such corporate action
as may, in the opinion of counsel, be necessary to increase its authorized and unissued shares of its preferred stock (and shares
of common stock for issuance on conversion of such shares) to a number of shares as shall be sufficient for such purposes. 

 

3. Replacement
of the Warrant. Subject to the receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or
mutilation of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory
in form and substance to the Company or, in the case of mutilation, on surrender and cancellation of this Warrant, the Company
at the expense of the Holder shall execute and deliver, in lieu of this Warrant, a new warrant of like tenor and amount.

 

    - 3 -

     

    

 

4. Transfer
of the Warrant.

 

(a) Warrant
Register. The Company shall maintain a register (the “Warrant Register”) containing the name
and address of the Holder or Holders. Until this Warrant is transferred on the Warrant Register in accordance herewith, the Company
may treat the Holder as shown on the Warrant Register as the absolute owner of this Warrant for all purposes, notwithstanding any
notice to the contrary. Any Holder of this Warrant (or of any portion of this Warrant) may change its address as shown on the Warrant
Register by written notice to the Company requesting a change.

 

(b) Warrant
Agent. The Company may appoint an agent for the purpose of maintaining the Warrant Register referred to in Section 4(a),
issuing the Shares or other securities then issuable upon the exercise of the rights under this Warrant, exchanging this Warrant,
replacing this Warrant or conducting related activities.

 

(c) Transferability
of the Warrant. Subject to the provisions of this Warrant with respect to compliance with the Securities Act of 1933, as
amended (the “Securities Act”) and limitations on assignments and transfers, including without limitation
compliance with the restrictions on transfer set forth in Section 5, title to this Warrant
may be transferred by endorsement (by the transferor and the transferee executing the assignment form attached as Exhibit B
(the “Assignment Form”)) and delivery in the same manner as a negotiable instrument transferable by endorsement
and delivery.

 

(d) Exchange
of the Warrant upon a Transfer. On surrender of this Warrant (and a properly endorsed Assignment Form) for exchange, subject
to the provisions of this Warrant with respect to compliance with the Securities Act and limitations on assignments and transfers,
the Company shall issue to or on the order of the Holder a new warrant or warrants of like tenor, in the name of the Holder or
as the Holder (on payment by the Holder of any applicable transfer taxes) may direct, for the number of shares issuable upon exercise
hereof, and the Company shall register any such transfer upon the Warrant Register. This Warrant (and the securities issuable upon
exercise of the rights under this Warrant) must be surrendered to the Company or its warrant or transfer agent, as applicable,
as a condition precedent to the sale, pledge, hypothecation or other transfer of any interest in any of the securities represented
hereby.

 

(e) Minimum
Transfer. This Warrant may not be transferred in part.

 

(f) Taxes.
In no event shall the Company be required to pay any stamp, duty, transfer, or other similar tax which may be payable in respect
of any transfer involved in the issue and delivery of any certificate in a name other than that of the Holder, and the Company
shall not be required to issue or deliver any such certificate unless and until the person or persons requesting the issue thereof
shall have paid to the Company the amount of such tax or shall have established to the satisfaction of the Company that such tax
has been paid or is not payable.

 

5. Restrictions
on Transfer of the Warrant and Shares; Compliance with Securities Laws. By acceptance of this Warrant, the Holder agrees to
comply with the following:

 

(a) Restrictions
on Transfers. Subject to Section 5(b), this Warrant may not be transferred or
assigned in whole or in part without the Company’s prior written consent (which shall not be unreasonably withheld or delayed),
and any attempt by Holder to transfer or assign any rights, duties or obligations that arise under this Warrant without such permission
shall be void. Any transfer of this Warrant or the Shares or the shares of common stock issuable upon conversion of the Shares
(the “Securities”) must be in compliance with all applicable federal and state securities laws. The Holder
agrees not to make any sale, assignment, transfer, pledge or other disposition of all or any portion of the Securities, or any
beneficial interest therein, unless and until the transferee thereof has agreed in writing for the benefit of the Company to take
and hold such Securities subject to, and to be bound by, the terms and conditions set forth in this Warrant to the same extent
as if the transferee were the original Holder hereunder, and

 

    - 4 -

     

    

 

(i) there
is then in effect a registration statement under the Securities Act covering such proposed disposition and such disposition is
made in accordance with such registration statement, or

 

(ii) (A) such
Holder shall have given prior written notice to the Company of such Holder’s intention to make such disposition and shall
have furnished the Company with a detailed description of the manner and circumstances of the proposed disposition, (B) the
transferee shall have confirmed to the satisfaction of the Company in writing, substantially in the form of Exhibit A-1, that
the Securities are being acquired (i) solely for the transferee’s own account and not as a nominee for any other party,
(ii) for investment and (iii) not with a view toward distribution or resale in violation of the Securities Act or applicable
state securities laws, and shall have confirmed such other matters related thereto as may be reasonably requested by the Company,
and (C) such Holder shall have furnished the Company, at the Holder’s expense, with (i)  an opinion of counsel,
reasonably satisfactory to the Company, to the effect that such disposition will not require registration of such Securities under
the Securities Act or (ii) a “no action” letter from the Securities and Exchange Commission to the effect that
the transfer of such Securities without registration will not result in a recommendation by the staff of the Securities and Exchange
Commission that action be taken with respect thereto, whereupon such Holder shall be entitled to transfer such Securities in accordance
with the terms of the notice delivered by the Holder to the Company. It is agreed that the Company will not require opinions of
counsel for transactions made pursuant to Rule 144 except in unusual circumstances.

 

(b) Permitted
Transfers. Permitted transfers include (i) a transfer not involving a change in beneficial ownership, or (ii) transactions
involving the disposition of Securities by any Holder to (x) a parent, subsidiary or other affiliate of a Holder that is a
corporation, (y) any of the Holder’s partners, members or other equity owners, or retired partners or members, or to
the estate of any of its partners, members or other equity owners or retired partners or members, or (z) a venture capital
fund or other investment fund or account that is controlled by or under common control with one or more general partners or managing
members of, or shares the same management company with, the Holder; provided, in each case, that (A) the Holder shall give
written notice to the Company of the Holder’s intention to effect such disposition and shall have furnished the Company with
a detailed description of the manner and circumstances of the proposed disposition, and (B) the transferee has agreed in writing
for the benefit of the Company to take and hold such Securities subject to, and to be bound by, the terms and conditions set forth
in this Warrant to the same extent as if the transferee were the original Holder hereunder.

 

(c) Investment
Representation Statement. Unless the rights under this Warrant are exercised pursuant to an effective registration statement
under the Securities Act that includes the Shares with respect to which the Warrant was exercised, it shall be a condition to any
exercise of the rights under this Warrant that the Holder shall have confirmed to the satisfaction of the Company in writing, substantially
in the form of Exhibit A-1, that the Shares so purchased are being acquired solely for the Holder’s own account and
not as a nominee for any other party, for investment and not with a view toward distribution or resale in violation of the Securities
Act or applicable state securities laws and that the Holder shall have confirmed such other matters related thereto as may be reasonably
requested by the Company.

 

(d) Securities
Law Legend. The Securities shall (unless otherwise permitted by the provisions of this Warrant) be stamped or imprinted
with a legend substantially similar to the following (in addition to any legend required by state securities laws):

 

    - 5 -

     

    

 

THE SECURITIES
REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE
SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED
EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS IN ACCORDANCE WITH APPLICABLE REGISTRATION REQUIREMENTS
OR AN EXEMPTION THEREFROM. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE ISSUER
THAT SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION OTHERWISE COMPLIES WITH THE ACT AND ANY APPLICABLE STATE SECURITIES
LAWS. This certificate must be surrendered to the coMPANY or its transfer agent as a condition
precedent to the sale, TRANSFER, pledge OR hypothecation of any interest in any of the securities represented hereby.

 

(e) Market
Stand-off Legend. The Shares and common stock issued upon exercise hereof or conversion thereof shall also be stamped or
imprinted with a legend in substantially the following form:

 

THE SHARES
REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE, INCLUDING A LOCK-UP PERIOD IN THE EVENT
OF A PUBLIC OFFERING, AS SET FORTH IN THE WARRANT PURSUANT TO WHICH THESE SHARES WERE ISSUED, A COPY OF WHICH MAY BE OBTAINED AT
THE PRINCIPAL OFFICE OF THE COMPANY.

 

(f) Instructions
Regarding Transfer Restrictions. The Holder consents to the Company making a notation on its records and giving instructions
to any transfer agent in order to implement the restrictions on transfer established in this Section 5.

 

(g) Removal
of Legend. The legend referring to federal and state securities laws identified in Section 5(d)
stamped on a certificate evidencing the Shares (and common stock issuable upon conversion thereof) and the stock transfer instructions
and record notations with respect to such securities shall be removed and the Company shall issue a certificate without such legend
to the holder of such securities if (i) such securities are registered under the Securities Act, or (ii) such holder
provides the Company with an opinion of counsel reasonably acceptable to the Company to the effect that a sale or transfer of such
securities may be made without registration or qualification.

 

6. Adjustments.
Subject to the expiration of this Warrant pursuant to Section 8, the number and kind
of shares purchasable hereunder and the Exercise Price therefor are subject to adjustment from time to time, as follows:

 

(a) Merger
or Reorganization. If at any time there shall be any reorganization, recapitalization, merger or consolidation (a “Reorganization”)
involving the Company (other than the transactions described in Sections 6(b) or 6(c) or as would cause the expiration of this
Warrant under Section 8) in which shares of the Company’s stock are converted into
or exchanged for securities, cash or other property, then, as a part of such Reorganization, lawful provision shall be made so
that the Holder shall thereafter be entitled to receive upon exercise of this Warrant, the kind and amount of securities, cash
or other property of the successor corporation resulting from such Reorganization, equivalent in value to that which a holder of
the Shares deliverable upon exercise of this Warrant would have been entitled in such Reorganization if the right to purchase the
Shares hereunder had been exercised immediately prior to such Reorganization. In any such case, appropriate adjustment (as determined
in good faith by the Board of Directors of the successor corporation) shall be made in the application of the provisions of this
Warrant with respect to the rights and interests of the Holder after such Reorganization to the end that the provisions of this
Warrant shall be applicable after the event, as near as reasonably may be, in relation to any shares or other securities deliverable
after that event upon the exercise of this Warrant.

 

    - 6 -

     

    

 

(b) Reclassification
of Shares. If the securities issuable upon exercise of this Warrant are changed into the same or a different number of
securities of any other class or classes by reclassification, capital reorganization, conversion of all outstanding shares of the
relevant class or series (other than as would cause the expiration of this Warrant pursuant to Section 8)
or otherwise (a “Reclassification”), then, in any such event, in lieu of the number of Shares which the
Holder would otherwise have been entitled to receive, the Holder shall have the right thereafter to exercise this Warrant for a
number of shares of such other class or classes of stock that a holder of the number of securities deliverable upon exercise of
this Warrant immediately before that change would have been entitled to receive in such Reclassification, all subject to further
adjustment as provided herein with respect to such other shares.

 

(c) Subdivisions
and Combinations. In the event that the outstanding shares of the securities issuable upon exercise of this Warrant are
subdivided (by stock split, by payment of a stock dividend or otherwise) into a greater number of shares of such securities, the
number of Shares issuable upon exercise of the rights under this Warrant immediately prior to such subdivision shall, concurrently
with the effectiveness of such subdivision, be proportionately increased, and the Exercise Price shall be proportionately decreased,
and in the event that the outstanding shares of the securities issuable upon exercise of this Warrant are combined (by reclassification
or otherwise) into a lesser number of shares of such securities, the number of Shares issuable upon exercise of the rights under
this Warrant immediately prior to such combination shall, concurrently with the effectiveness of such combination, be proportionately
decreased, and the Exercise Price shall be proportionately increased.

 

(d) Notice
of Adjustments. Upon any adjustment in accordance with this Section 6, the Company
shall give notice thereof to the Holder, which notice shall state the event giving rise to the adjustment, the Exercise Price as
adjusted and the number of securities or other property purchasable upon the exercise of the rights under this Warrant, setting
forth in reasonable detail the method of calculation of each. The Company shall, upon the written request of any Holder, furnish
or cause to be furnished to such Holder a certificate setting forth (i) such adjustments, (ii) the Exercise Price at
the time in effect and (iii) the number of securities and the amount, if any, of other property that at the time would be
received upon exercise of this Warrant.

 

7. Notification
of Certain Events. Prior to the expiration of this Warrant pursuant to Section 8,
in the event that the Company shall authorize:

 

(a) the
issuance of any dividend or other distribution on the capital stock of the Company (other than (i) dividends or distributions
otherwise provided for in Section 6, (ii) repurchases of common stock issued to
or held by employees, officers, directors or consultants of the Company or its subsidiaries upon termination of their employment
or services pursuant to agreements providing for the right of said repurchase; (iii) repurchases of common stock issued to
or held by employees, officers, directors or consultants of the Company or its subsidiaries pursuant to rights of first refusal
or first offer contained in agreements providing for such rights; or (iv) repurchases of capital stock of the Company in connection
with the settlement of disputes with any stockholder), whether in cash, property, stock or other securities;

 

(b) the
voluntary liquidation, dissolution or winding up of the Company; or

 

(c) any
transaction resulting in the expiration of this Warrant pursuant to Section 8(b), or constituting a firm commitment underwritten
initial public offering pursuant to an effective registration statement filed under the Securities Act covering the offering and
sale of the Company’s common stock;

 

    - 7 -

     

    

 

the Company shall send
to the Holder of this Warrant at least two (2) business days prior written notice of the date on which a record shall be taken
for any such dividend or distribution specified in clause (a) or the expected effective date of any such other event specified
in clause (b) or (c), as applicable. The notice provisions set forth in this section may be shortened or waived prospectively
or retrospectively by the consent of the holders of a majority of the Shares issuable upon exercise of the rights under the Warrants.

 

(d) The
Holder may exercise this Warrant conditioned upon (and effective immediately prior to) consummation of any transaction set forth
in this Section 7.

 

8. Expiration
of the Warrant. This Warrant shall expire and shall no longer be exercisable as of the earlier of:

 

(a) 5:00
p.m., Pacific time, on September 2, 2029;

 

(b) (i)
the acquisition of the Company by another entity by means of any transaction or series of related transactions to which the Company
is a party (including, without limitation, any stock acquisition, reorganization, merger or consolidation, but excluding any sale
of stock for capital raising purposes and any transaction effected primarily for purposes of changing the Company’s jurisdiction
of incorporation) other than a transaction or series of related transactions in which the holders of the voting securities of the
Company outstanding immediately prior to such transaction or series of related transactions retain, immediately after such transaction
or series of transactions, as a result of shares in the Company held by such holders prior to such transaction or series of transactions,
at least a majority of the total voting power represented by the outstanding voting securities of the Company or such other surviving
or resulting entity (or if the Company or such other surviving or resulting entity is a wholly-owned subsidiary immediately following
such acquisition, its parent), or (ii) a sale, lease or other disposition of all or substantially all of the assets of the
Company and its subsidiaries taken as a whole by means of any transaction or series of related transactions, except where such
sale, lease or other disposition is to a wholly-owned subsidiary of the Company; or

 

(c) Immediately
prior to the closing of a firm commitment underwritten initial public offering pursuant to an effective registration statement
filed under the Securities Act covering the offering and sale of the Company’s common stock.

 

9. No
Rights as a Stockholder. Nothing contained herein shall entitle the Holder to any rights as a stockholder of the Company or
to be deemed the holder of any securities that may at any time be issuable on the exercise of the rights hereunder for any purpose
nor shall anything contained herein be construed to confer upon the Holder, as such, any right to vote for the election of directors
or upon any matter submitted to stockholders at any meeting thereof, or to give or withhold consent to any corporate action (whether
upon any recapitalization, issuance of stock, reclassification of stock, change of par value or change of stock to no par value,
consolidation, merger, conveyance or otherwise) or to receive notice of meetings, or to receive dividends or subscription rights
or any other rights of a stockholder of the Company until the rights under the Warrant shall have been exercised and the Shares
purchasable upon exercise of the rights hereunder shall have become deliverable as provided herein.

 

10. Market
Stand-off. The Holder of this Warrant hereby agrees that, during the period commencing on the date of the final prospectus
relating to an underwritten public offering of the Company’s Common Stock under the Securities Act and ending on the date
specified by the Company and the managing underwriter (such period not to exceed 180 days), such Holder will not, without the prior
written consent of the Company or the managing underwriter:

 

    - 8 -

     

    

 

(a) lend,
offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant
any option, right, or warrant to purchase or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock,
or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock, held immediately before
the effective date of the registration statement for such offering; or

 

(b) enter
into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership
of such securities, whether any such transaction described in clause (a) above is to be settled by delivery of Common Stock or
other securities, in cash, or otherwise.

 

The foregoing provisions
of this Section 10 shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, and shall
be applicable to the Holder of this Warrant only if all officers, directors, and stockholders individually owning more than one
percent (1%) of the Company’s outstanding Common Stock (after giving effect to conversion into Common Stock of all outstanding
Preferred Stock of the Company) are similarly bound. For purposes of this Section 10, the term “Company” shall include
any wholly-owned subsidiary of the Company into which the Company merges or consolidates. In order to enforce the foregoing covenant,
the Company shall have the right to place restrictive legends on the certificates representing the shares subject to this Section
10 and to impose stop transfer instructions with respect to such shares until the end of such period. The underwriters in connection
with such registration are intended third party beneficiaries of this Section 10 and shall have the right, power, and authority
to enforce the provisions hereof as though they were a party hereto. The Holder of this Warrant further agrees to execute such
agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this
Section 10 or that are necessary to give further effect thereto.

 

11. Representations
and Warranties of the Holder. By acceptance of this Warrant, the Holder represents and warrants to the Company as follows:

 

(a) No
Registration. The Holder understands that the Securities have not been, and will not be, registered under the Securities
Act by reason of a specific exemption from the registration provisions of the Securities Act, the availability of which depends
upon, among other things, the bona fide nature of the investment intent and the accuracy of the Holder’s representations
as expressed herein or otherwise made pursuant hereto.

 

(b) Investment
Intent. The Holder is acquiring the Securities for investment for its own account, not as a nominee or agent, and not with
a view to, or for resale in connection with, any distribution thereof in violation of the Securities Act or applicable state securities
laws. The Holder has no present intention of selling, granting any participation in, or otherwise distributing the Securities,
nor does it have any contract, undertaking, agreement or arrangement for the same.

 

(c) Investment
Experience. The Holder has substantial experience in evaluating and investing in private placement transactions of securities
in companies similar to the Company, and has such knowledge and experience in financial or business matters so that it is capable
of evaluating the merits and risks of its investment in the Company and protecting its own interests.

 

(d) Speculative
Nature of Investment. The Holder understands and acknowledges that the Company has a limited financial and operating history
and that its investment in the Company is highly speculative and involves substantial risks. The Holder can bear the economic risk
of its investment and is able, without impairing its financial condition, to hold the Securities for an indefinite period of time
and to suffer a complete loss of its investment.

 

    - 9 -

     

    

 

(e) Access
to Data. The Holder has had an opportunity to ask questions of officers of the Company, which questions were answered to
its satisfaction. The Holder believes that it has received all the information that it considers necessary or appropriate for deciding
whether to acquire the Securities. The Holder understands that any such discussions, as well as any information issued by the Company,
were intended to describe certain aspects of the Company’s business and prospects, but were not necessarily a thorough or
exhaustive description. The Holder acknowledges that any business plans prepared by the Company have been, and continue to be,
subject to change and that any projections included in such business plans or otherwise are necessarily speculative in nature,
and it can be expected that some or all of the assumptions underlying the projections will not materialize or will vary significantly
from actual results.

 

(f) Accredited
Investor. The Holder is an “accredited investor” within the meaning of Regulation D, Rule 501(a),
promulgated by the Securities and Exchange Commission and agrees to submit to the Company such further assurances of such status
as may be reasonably requested by the Company.

 

(g) Residency.
The residency of the Holder (or, in the case of a partnership or corporation, such entity’s principal place of business)
is correctly set forth on the signature page hereto.

 

(h) Restrictions
on Resales. The Holder acknowledges that the Securities must be held indefinitely unless subsequently registered under
the Securities Act or an exemption from such registration is available. The Holder is aware of the provisions of Rule 144
promulgated under the Securities Act, which permit resale of shares purchased in a private placement subject to the satisfaction
of certain conditions, which may include, among other things, the availability of certain current public information about the
Company; the resale occurring not less than a specified period after a party has purchased and paid for the security to be sold;
the number of shares being sold during any three-month period not exceeding specified limitations; the sale being effected through
a “broker’s transaction,” a transaction directly with a “market maker” or a “riskless principal
transaction” (as those terms are defined in the Securities Act or the Securities Exchange Act of 1934, as amended, and the
rules and regulations promulgated thereunder); and the filing of a Form 144 notice, if applicable. The Holder acknowledges and
understands that the Company may not be satisfying the current public information requirement of Rule 144 at the time the
Holder wishes to sell the Securities and that, in such event, the Holder may be precluded from selling the Securities under Rule 144
even if the other applicable requirements of Rule 144 have been satisfied. The Holder acknowledges that, in the event the
applicable requirements of Rule 144 are not met, registration under the Securities Act or an exemption from registration will
be required for any disposition of the Securities. The Holder understands that, although Rule 144 is not exclusive, the Securities
and Exchange Commission has expressed its opinion that persons proposing to sell restricted securities received in a private offering
other than in a registered offering or pursuant to Rule 144 will have a substantial burden of proof in establishing that an
exemption from registration is available for such offers or sales and that such persons and the brokers who participate in the
transactions do so at their own risk.

 

(i) No
Public Market. The Holder understands and acknowledges that no public market now exists for any of the securities issued
by the Company and that the Company has made no assurances that a public market will ever exist for the Company’s securities.

 

(j) Brokers
and Finders. The Holder has not engaged any brokers, finders or agents in connection with the Securities, and the Company
has not incurred nor will incur, directly or indirectly, as a result of any action taken by the Holder, any liability for brokerage
or finders’ fees or agents’ commissions or any similar charges in connection with the Securities.

 

    - 10 -

     

    

 

(k) Legal
Counsel. The Holder has had the opportunity to review this Warrant, the exhibits and schedules attached hereto and the
transactions contemplated by this Warrant with its own legal counsel. The Holder is not relying on any statements or representations
of the Company or its agents for legal advice with respect to this investment or the transactions contemplated by this Warrant.

 

(l) Tax
Advisors. The Holder has reviewed with its own tax advisors the U.S. federal, state and local and non-U.S. tax consequences
of this investment and the transactions contemplated by this Warrant. With respect to such matters, the Holder relies solely on
any such advisors and not on any statements or representations of the Company or any of its agents, written or oral. The Holder
understands that it (and not the Company) shall be responsible for its own tax liability that may arise as a result of this investment
and the transactions contemplated by this Warrant.

 

12. Miscellaneous.

 

(a) Amendments.
Except as expressly provided herein, neither this Warrant nor any term hereof may be amended, waived, discharged or terminated
other than by a written instrument referencing this Warrant and signed by the Company and the holders of Warrants issued pursuant
to the Agreement and representing not less than sixty percent (60%) of the Shares issuable upon exercise of any and all outstanding
Warrants issued pursuant to the Agreement, which sixty percent (60%) does not need to include the consent of the Holder; provided,
however, that no such amendment, waiver or termination shall (i) increase the Exercise Price or (ii) otherwise decrease
the number of Shares issuable pursuant to Section 1(b). Any amendment, waiver, discharge or termination effected in accordance
with this Section 12(a) shall be binding upon each holder of the Warrants, each future
holder of such Warrants and the Company.

 

(b) Waivers.
No waiver of any single breach or default shall be deemed a waiver of any other breach or default theretofore or thereafter occurring.

 

(c) Notices.
All notices and other communications required or permitted hereunder shall be in writing and shall be mailed by registered or certified
mail, postage prepaid, sent by facsimile or electronic mail (if to the Holder) or otherwise delivered by hand, messenger or courier
service addressed:

 

(i) if
to the Holder, to the Holder at the Holder’s address, facsimile number or electronic mail address as shown in the Company’s
records, as may be updated in accordance with the provisions hereof, or until any such Holder so furnishes an address, facsimile
number or electronic mail address to the Company, then to and at the address, facsimile number or electronic mail address of the
last holder of this Warrant for which the Company has contact information in its records; or

 

(ii) if
to the Company, to the attention of the President or Chief Financial Officer of the Company at the Company’s address as shown
on the signature page hereto, or at such other address as the Company shall have furnished to the Holder, with a copy to Fenwick
& West, LLP, Silicon Valley Center, 801 California Street, Mountain View, California 94041, Attn: Michael Esquivel.

 

Each such notice or other
communication shall for all purposes of this Warrant be treated as effective or having been given (i) if delivered by hand,
messenger or courier service, when delivered, or (ii) if sent by mail, at the earlier of its receipt or 72 hours after
the same has been deposited in a regularly maintained receptacle for the deposit of the United States mail, addressed and mailed
as aforesaid, or (iii) if sent by facsimile, upon confirmation of facsimile transfer or, if sent by electronic mail, upon
confirmation of delivery when directed to the relevant electronic mail address. In the event of any conflict between the Company’s
books and records and this Warrant or any notice delivered hereunder, the Company’s books and records will control absent
fraud or error.

 

    - 11 -

     

    

 

(d) Governing
Law. This Warrant and all actions arising out of or in connection with this Warrant shall be governed by and construed
in accordance with the laws of the State of Delaware, without regard to the conflicts of law provisions of the State of Delaware,
or of any other state.

 

(e) Jurisdiction
and Venue. Each of the Holder and the Company irrevocably consents to the exclusive jurisdiction and venue of any court
within the State of Delaware, in connection with any matter based upon or arising out of this Warrant or the matters contemplated
herein, and agrees that process may be served upon them in any manner authorized by the laws of the State of Delaware for such
persons.

 

(f) Titles
and Subtitles. The titles and subtitles used in this Warrant are used for convenience only and are not to be considered
in construing or interpreting this Warrant. All references in this Warrant to sections, paragraphs and exhibits shall, unless otherwise
provided, refer to sections and paragraphs hereof and exhibits attached hereto.

 

(g) Severability.
If any provision of this Warrant becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void,
portions of such provision, or such provision in its entirety, to the extent necessary, shall be severed from this Warrant, and
such illegal, unenforceable or void provision shall be replaced with a valid and enforceable provision that will achieve, to the
extent possible, the same economic, business and other purposes of the illegal, unenforceable or void provision. The balance of
this Warrant shall be enforceable in accordance with its terms.

 

(h) Waiver
of Jury Trial. Each of the Holder and the
Company waives, to the fullest extent permitted by law, any and all right to trial by jury in any legal proceeding (whether based
on contract, tort or otherwise) arising out of or related to this Warrant. This paragraph shall not restrict the Holder
or the Company from exercising remedies under the Uniform Commercial Code or from exercising pre-judgment remedies under applicable
law.

 

(i) California
Corporate Securities Law. THE SALE OF THE SECURITIES THAT ARE THE SUBJECT OF THIS WARRANT HAS NOT BEEN QUALIFIED WITH THE
COMMISSIONER OF BUSINESS OVERSIGHT OF THE STATE OF CALIFORNIA AND THE ISSUANCE OF SUCH SECURITIES OR THE PAYMENT OR RECEIPT OF
ANY PART OF THE CONSIDERATION THEREFOR PRIOR TO SUCH QUALIFICATION IS UNLAWFUL, UNLESS THE SALE OF SECURITIES IS EXEMPT FROM QUALIFICATION
BY SECTION 25100, 25102, OR 25105 OF THE CALIFORNIA CORPORATIONS CODE. THE RIGHTS OF ALL PARTIES TO THIS WARRANT ARE EXPRESSLY
CONDITIONED UPON THE QUALIFICATION BEING OBTAINED, UNLESS THE SALE IS SO EXEMPT.

 

(j) Saturdays,
Sundays and Holidays. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall be a Saturday, Sunday or U.S. federal holiday, then such action may be taken or such right may be exercised
on the next succeeding day that is not a Saturday, Sunday or U.S. federal holiday.

 

(k) Rights
and Obligations Survive Exercise of the Warrant. Except as otherwise provided herein, the rights and obligations of the
Company and the Holder under this Warrant shall survive exercise of this Warrant.

 

(l) Entire
Agreement. Except as expressly set forth herein, this Warrant (including the exhibits attached hereto) constitutes the
entire agreement and understanding of the Company and the Holder with respect to the subject matter hereof and supersede all prior
agreements and understandings relating to the subject matter hereof.

 

(signature page follows)

 

    - 12 -

     

    

 

The Company and the
Holder sign this Warrant as of the date stated on the first page.

 

	 	AUGMEDIX, INC.
	 	 
	 	By:	 
	 	 
	 	Name:	 
	 	 
	 	Title:	 
	 	 
	 	Address:
	 	 
	 	
	 	 
	 	
	 	 
	 	

 

	AGREED AND ACKNOWLEDGED,	 
	 	 	 
	[________________________] 	 	 
	 	 	 
	By:		 
		Signature 	 
	 	 	 
		Name and Title 	 
	 	 	 
	Address:	 	 
		 	 
	 	 	 
		 	 
	 	 	 
		 	 

 

(Signature Page to Warrant to Purchase
Shares of Series B Preferred Stock of Augmedix, Inc.)

 

     

     

    

 

EXHIBIT A

 

NOTICE OF EXERCISE

 

	TO:	AUGMEDIX, INC. (the “Company”)
	 	 
	Attention:	President

 

		(i)	Exercise. The undersigned elects to purchase the following pursuant to the terms of the
attached warrant:

 

	 	Number of
    shares:	 
	 	 	 
	 	Type of security:	 
	 	 	 
	 	If conditional exercise, indicate condition herein:	 
	 	 	 
	 	 
	 	 
	 	 

 

		(ii)	Method of Exercise. The undersigned elects to exercise the attached warrant pursuant to:

 

		☐	A cash payment, and tenders herewith payment of the purchase price for such shares in full, together
with all applicable transfer taxes, if any.

 

		☐	The net issue exercise provisions of Section 2(b) of the attached warrant.

 

		(iii)	Stock Certificate. Please issue a certificate or certificates representing the shares in
the name of:

 

		☐	The undersigned

 

		☐	Other	Name:	 
		 		Address:	 
	 	 	 	 

 

		(iv)	Unexercised Portion of the Warrant. Please issue a new warrant for the unexercised portion
of the attached warrant in the name of:

 

		☐	The undersigned

 

		☐	Other	Name:	 
		 		Address:	 
	 	 	 	 

 

		☐	Not applicable

 

    A-1

     

    

 

		(v)	Investment Intent. The undersigned represents and warrants that the aforesaid shares are
being acquired for investment for its own account, not as a nominee or agent, and not with a view to, or for resale in connection
with, the distribution thereof in violation of the Securities Act of 1933, as amended, or applicable state securities laws, and
that the undersigned has no present intention of selling, granting any participation in, or otherwise distributing the shares,
nor does it have any contract, undertaking, agreement or arrangement for the same, and all representations and warranties of the
undersigned set forth in Section 11 of the attached warrant are true and correct as of the date hereof.

 

		(vi)	Investment Representation Statement and Market Stand-Off Agreement. The undersigned has
executed, and delivers herewith, an Investment Representation Statement and Market Stand-Off Agreement in a form substantially
similar to the form attached to the warrant as Exhibit A-1.

 

		(vii)	Consent to Receipt of Electronic Notice. Subject to the limitations set forth in Delaware
General Corporation Law §232(e), the undersigned consents to the delivery of any notice to stockholders given by the Company
under the Delaware General Corporation Law or the Company’s certificate of incorporation or bylaws by (i) facsimile
telecommunication to the facsimile number provided below (or to any other facsimile number for the undersigned in the Company’s
records), (ii) electronic mail to the electronic mail address provided below (or to any other electronic mail address for
the undersigned in the Company’s records), (iii) posting on an electronic network together with separate notice to the
undersigned of such specific posting or (iv) any other form of electronic transmission (as defined in the Delaware General
Corporation Law) directed to the undersigned. This consent may be revoked by the undersigned by written notice to the Company and
may be deemed revoked in the circumstances specified in Delaware General Corporation Law §232.

 

	 	 
	 	(Print name of the warrant holder)
	 	 
	 	 
	 	(Signature)
	 	 
	 	 
	 	(Name and title of signatory, if applicable)
	 	 
	 	 
	 	(Date)
	 	 
	 	 
	 	(Fax number)
	 	 
	 	 
	 	(Email address)
	 	 

 

(Signature page to the Notice of Exercise)

 

    A-2

     

    

 

EXHIBIT A-l

 

INVESTMENT REPRESENTATION
STATEMENT

AND

MARKET STAND-OFF AGREEMENT

 

	INVESTOR:	 
	 	 
	COMPANY:	AUGMEDIX, INC.
	 	 
	SECURITIES:	THE WARRANT ISSUED ON ______________, 2019 (THE “WARRANT”) AND THE SECURITIES ISSUED OR ISSUABLE UPON EXERCISE THEREOF (INCLUDING UPON SUBSEQUENT CONVERSION OF THOSE SECURITIES)
	 	 
	DATE:	 	 

 

In connection with
the purchase or acquisition of the above-listed Securities, the undersigned Investor represents and warrants to, and agrees with,
the Company as follows:

 

1. No
Registration. The Investor understands that the Securities have not been, and will not be, registered under the Securities
Act of 1933, as amended (the “Securities Act”), by reason of a specific exemption from the registration
provisions of the Securities Act, the availability of which depends upon, among other things, the bona fide nature of the
investment intent and the accuracy of the Investor’s representations as expressed herein or otherwise made pursuant hereto.

 

2. Investment
Intent. The Investor is acquiring the Securities for investment for its own account, not as a nominee or agent, and not with
a view to, or for resale in connection with, any distribution thereof in violation of the Securities Act or applicable state securities
laws. The Investor has no present intention of selling, granting any participation in, or otherwise distributing the Securities,
nor does it have any contract, undertaking, agreement or arrangement for the same.

 

3. Investment
Experience. The Investor has substantial experience in evaluating and investing in private placement transactions of securities
in companies similar to the Company, and has such knowledge and experience in financial or business matters so that it is capable
of evaluating the merits and risks of its investment in the Company and protecting its own interests.

 

4. Speculative
Nature of Investment. The Investor understands and acknowledges that the Company has a limited financial and operating history
and that its investment in the Company is highly speculative and involves substantial risks. The Investor can bear the economic
risk of its investment and is able, without impairing its financial condition, to hold the Securities for an indefinite period
of time and to suffer a complete loss of its investment.

 

5. Access
to Data. The Investor has had an opportunity to ask questions of officers of the Company, which questions were answered to
its satisfaction. The Investor believes that it has received all the information that it considers necessary or appropriate for
deciding whether to acquire the Securities. The Investor understands that any such discussions, as well as any information issued
by the Company, were intended to describe certain aspects of the Company’s business and prospects, but were not necessarily
a thorough or exhaustive description. The Investor acknowledges that any business plans prepared by the Company have been, and
continue to be, subject to change and that any projections included in such business plans or otherwise are necessarily speculative
in nature, and it can be expected that some or all of the assumptions underlying the projections will not materialize or will vary
significantly from actual results.

 

    A-1-1

     

    

 

6. Accredited
Investor. The Investor is an “accredited investor” within the meaning of Regulation D, Rule 501(a), promulgated
by the Securities and Exchange Commission and agrees to submit to the Company such further assurances of such status as may be
reasonably requested by the Company.

 

7. Residency.
The residency of the Investor (or, in the case of a partnership or corporation, such entity’s principal place of business)
is correctly set forth on the signature page hereto.

 

8. Restrictions
on Resales. The Investor acknowledges that the Securities must be held indefinitely unless subsequently registered under the
Securities Act or an exemption from such registration is available. The Investor is aware of the provisions of Rule 144 promulgated
under the Securities Act, which permit resale of shares purchased in a private placement subject to the satisfaction of certain
conditions, which may include, among other things, the availability of certain current public information about the Company; the
resale occurring not less than a specified period after a party has purchased and paid for the security to be sold; the number
of shares being sold during any three-month period not exceeding specified limitations; the sale being effected through a “broker’s
transaction,” a transaction directly with a “market maker” or a “riskless principal transaction”
(as those terms are defined in the Securities Act or the Securities Exchange Act of 1934, as amended, and the rules and regulations
promulgated thereunder); and the filing of a Form 144 notice, if applicable. The Investor acknowledges and understands that the
Company may not be satisfying the current public information requirement of Rule 144 at the time the Investor wishes to sell
the Securities and that, in such event, the Investor may be precluded from selling the Securities under Rule 144 even if the
other applicable requirements of Rule 144 have been satisfied. The Investor understands and acknowledges that, in the event
the applicable requirements of Rule 144 are not met, registration under the Securities Act or an exemption from registration
will be required for any disposition of the Securities. The Investor understands that, although Rule 144 is not exclusive,
the Securities and Exchange Commission has expressed its opinion that persons proposing to sell restricted securities received
in a private offering other than in a registered offering or pursuant to Rule 144 will have a substantial burden of proof
in establishing that an exemption from registration is available for those offers or sales and that those persons and the brokers
who participate in the transactions do so at their own risk.

 

9. No
Public Market. The Holder understands and acknowledges that no public market now exists for any of the securities issued by
the Company and that the Company has made no assurances that a public market will ever exist for the Company’s securities.

 

10. Brokers
and Finders. The Investor has not engaged any brokers, finders or agents in connection with the Securities, and the Company
has not incurred nor will incur, directly or indirectly, as a result of any action taken by the Investor, any liability for brokerage
or finders’ fees or agents’ commissions or any similar charges in connection with the Securities.

 

11. Legal
Counsel. The Investor has had the opportunity to review the Warrant, the exhibits and schedules attached thereto and the transactions
contemplated by the Warrant with its own legal counsel. The Investor is not relying on any statements or representations of the
Company or its agents for legal advice with respect to this investment or the transactions contemplated by the Warrant.

 

12. Tax
Advisors. The Investor has reviewed with its own tax advisors the U.S. federal, state and local and non-U.S. tax consequences
of this investment and the transactions contemplated by the Warrant. With respect to such matters, the Investor relies solely on
such advisors and not on any statements or representations of the Company or any of its agents, written or oral. The Investor understands
that it (and not the Company) shall be responsible for its own tax liability that may arise as a result of this investment or the
transactions contemplated by the Warrant.

 

    A-1-2

     

    

 

13. Market
Stand-off. The Investor hereby agrees that, during the period commencing on the date of the final prospectus relating to an
underwritten public offering of the Company’s Common Stock under the Securities Act and ending on the date specified by the
Company and the managing underwriter (such period not to exceed 180 days), such Investor will not, without the prior written consent
of the Company or the managing underwriter:

 

(a) lend,
offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant
any option, right, or warrant to purchase or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock,
or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock, held immediately before
the effective date of the registration statement for such offering; or

 

(b) enter
into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership
of such securities, whether any such transaction described in clause (a) above is to be settled by delivery of Common Stock or
other securities, in cash, or otherwise.

 

The foregoing provisions
of this Section 13 shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, and shall
be applicable to the Investor only if all officers, directors, and stockholders individually owning more than one percent (1%)
of the Company’s outstanding Common Stock (after giving effect to conversion into Common Stock of all outstanding Preferred
Stock of the Company) are similarly bound. For purposes of this Section 13, the term “Company” shall include any wholly-owned
subsidiary of the Company into which the Company merges or consolidates. In order to enforce the foregoing covenant, the Company
shall have the right to place restrictive legends on the certificates representing the shares subject to this Section 13 and to
impose stop transfer instructions with respect to such shares until the end of such period. The underwriters in connection with
such registration are intended third party beneficiaries of this Section 13 and shall have the right, power, and authority to enforce
the provisions hereof as though they were a party hereto. The Investor further agrees to execute such agreements as may be reasonably
requested by the underwriters in connection with such registration that are consistent with this Section 13 or that are necessary
to give further effect thereto.

 

(signature page follows)

 

    A-1-3

     

    

 

The Investor is signing
this Investment Representation Statement and Market Stand-Off Agreement on the date first written above.

 

	 	INVESTOR
	 	 
	 	 
	 	(Print name of the investor)
	 	 
	 	 
	 	(Signature)
	 	 
	 	 
	 	(Name and title of signatory, if applicable)
	 	 
	 	 
	 	(Street address)
	 	 
	 	 
	 	(City, state and ZIP)

 

    A-1-4

     

    

 

EXHIBIT B

 

ASSIGNMENT FORM

 

	ASSIGNOR:	 
	 	 
	COMPANY:	AUGMEDIX, INC. 
	 	 
	WARRANT:	THE WARRANT TO PURCHASE SHARES OF SERIES B PREFERRED STOCK ISSUED ON __________________, 2019 (THE “WARRANT”)
	 	 
	DATE:	 	 

 

		(i)	Assignment. The undersigned registered holder of the Warrant (“Assignor”)
assigns and transfers to the assignee named below (“Assignee”) all of the rights of Assignor under the
Warrant, with respect to the number of shares set forth below:

 

	 	Name of Assignee:	 
	 	 	 
	 	Address of Assignee:	 
	 	 	 
	 	 	 
	 	 	 
	 	Number of Shares Assigned:	 

 

and does irrevocably
constitute and appoint ______________________ as attorney to make such transfer on the books of Augmedix, Inc., maintained for
the purpose, with full power of substitution in the premises.

 

		(ii)	Obligations of Assignee. Assignee agrees to take and hold the Warrant and any shares of
stock to be issued upon exercise of the rights thereunder (and any shares issuable upon conversion thereof) (the “Securities”)
subject to, and to be bound by, the terms and conditions set forth in the Warrant to the same extent as if Assignee were the original
holder thereof.

 

		(iii)	Investment Intent. Assignee represents and warrants that the Securities are being acquired
for investment for its own account, not as a nominee or agent, and not with a view to, or for resale in connection with, the distribution
thereof in violation of the Securities Act of 1933, as amended, or applicable state securities laws, and that Assignee has no present
intention of selling, granting any participation in, or otherwise distributing the shares, nor does it have any contract, undertaking,
agreement or arrangement for the same, and all representations and warranties set forth in Section 11 of the Warrant are true
and correct as to Assignee as of the date hereof.

 

		(iv)	Investment Representation Statement and Market Stand-Off Agreement. Assignee has executed,
and delivers herewith, an Investment Representation Statement and Market Stand-Off Agreement in a form substantially similar to
the form attached to the Warrant as Exhibit A-1.

 

    B-1

     

    

 

Assignor and Assignee
are signing this Assignment Form on the date first set forth above.

 

	ASSIGNOR	 	ASSIGNEE
	 	 	 
	 	 	 
	(Print name of Assignor)	 	(Print name of Assignee)
	 	 	 
	 	 	 
	 	 	 
	(Signature of Assignor)	 	(Signature of Assignee)
	 	 	 
	 	 	 
	 	 	 
	(Print name of signatory, if applicable)	 	(Print name of signatory, if applicable)
	 	 	 
	 	 	 
	 	 	 
	(Print title of signatory, if applicable)	 	(Print title of signatory, if applicable)
	 	 	 
	Address:	 	Address:
	 	 	 
	 	 	 
	 	 	 
	 	 	 

 

 

B-2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}]]